Current global research landscape on COVID-19 and cancer: Bibliometric and visualization analysis

Table 1 Publication contributions of the top 10 productive countries

Ranking	Country	Number of documents	%
1st	United States	2025	28.87
2nd	Italy	964	13.74
3rd	United Kingdom	839	11.96
4th	China	538	7.67
5th	India	489	6.97
6th	France	403	5.74
7th	Canada	363	5.17
8th	Germany	349	4.98
9th	Spain	327	4.66
10th	Australia	237	3.38

Table 2 Top ten active institutions/organizations on research related to coronavirus disease 2019 and cancer

Ranking	Institution	Country	n	%
1st	University of Texas MD Anderson Cancer Center	USA	205	2.92
2nd	Memorial Sloan-Kettering Cancer Center	USA	176	2.51
3rd	Harvard Medical School	USA	155	2.21
4th	Dana-Farber Cancer Institute	USA	152	2.17
5th	University of Toronto	Canada	132	1.88
5th	Università degli Studi di Milano	Italy	127	1.81
7th	Istituto Europeo di Oncologia	Italy	121	1.72
8th	INSERM	France	120	1.71
9th	Fondazione IRCCS Istituto Nazionale dei Tumori, Milan	Italy	119	1.70
10th	Tata Memorial Hospital	India	116	1.65

Table 3 Top ten active journals on research related to coronavirus disease 2019 and cancer

Ranking	Journal	n	%	IF
1st	European Journal of Cancer	106	1.51	9.162
2nd	Frontiers in Oncology	104	1.48	6.244
3rd	Cancers	102	1.45	6.639
4th	Pediatric Blood and Cancer	95	1.35	3.167
5th	Lancet Oncology	90	1.28	41.316
6th	Supportive Care in Cancer	86	1.23	3.603
7th	Cancer	81	1.15	6.860
8th	JAMA Oncology	75	1.07	31.777
9th	JCO Oncology Practice	73	1.04	NA
10th	Advances in Radiation Oncology	60	0.86	NA

IF: Impact factor; NA: Not available.

Table 4 List of the top 10 cited articles for coronavirus disease 2019 studies related to cancer between January 1, 2020, and June 21, 2022

Ranking	Ref.	Title	Year	Source title	Cited by	Impact Index Per Article1
1st	Liang et al[46]	“Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China”	2020	The Lancet Oncology	2498	1017.0
2nd	Zhang et al[47]	“Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China”	2020	Annals of Oncology	859	296.0
3rd	Tian et al[49]	“Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer”	2020	Journal of Thoracic Oncology	835	315.5
4th	Kuderer et al[12]	“Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study”	2020	The Lancet	825	292.5
5th	Dai et al[9]	“Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak	2020	Cancer Discovery	774	118.5
6th	Yu et al[50]	SARS-CoV-2” “Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan, China”	2020	JAMA Oncology	659	236.0
7th	Maringe et al[48]	“The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study”	2020	The Lancet Oncology	579	189.0
8th	Lee et al[10]	“COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study”	2020	The Lancet	574	210.5
9th	Mehta et al[11]	“Case fatality rate of cancer patients with COVID-19 in a New York Hospital system”	2020	Cancer Discovery	426	158.5
10th	Feldmann et al[51]	“Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed”	2020	The Lancet	340	140.0

¹The Impact Index Per Article is presented based on Reference Citation Analysis.